Digital Allogeneic Cell Therapy Summit 2020

Memo

The digital 2nd Allogeneic Cell Therapies Summit is the only meeting completely focussed on advancing the development of off-the-shelf therapies by advancing cryopreservation techniques and decreasing cost through industrialized manufacturing. Network with 250 industry leaders to discuss novel genetic engineering techniques that overcome rejection and avoid GVHD to pave the way for further breakthroughs in patient treatment.   Tickets: https://go.evvnt.com/601494-1?pid=5569  Date and Time: On Monday October 26, 2020 at 8:00 am ends Wednesday October 28, 2020 at 6:00 pm Prices:Conference + 2 Workshops (Drug Developer Early Registration Rate): USD 2517.00,Conference + 1 Workshop (Drug Developer Early Registration Rate): USD 2168.00,Conference Only (Drug Developer Early Registration Rate): USD 1819.00,Workshop Only (Drug Developer Early Registration Rate): USD 489.00,Conference + 2 Workshops (Drug Developer Standard Rate): USD 3007.00,Conference + 1 Workshop (Drug Developer Standard Rate): USD 2588.00,Conference Only (Drug Developer Standard Rate): USD 2169.00,Workshop Only (Drug Developer Standard Rate): USD 489.00 Speakers: Jo Brewer VP, Allogeneic Research Adaptimmune, Anthony Colenburg Director of Quality Adicet Bio, Peter Flynn CTO Artiva Biotherapeutics, Blake Aftab VP, Preclinical and Translational Science Atara Biotherapeutics, Manny Duenas VP, Head of Global Market Access Atara Biotherapeutics, Maksim Mamonkin Assistant Professor Baylor College of Medicine, Joy Aho Senior Product Manager Be The Match BioTherapies, Ian McNiece CSO Biocardia, Aura Mackenzie Senior Director Bluebird Bio, Robert Deans CIO Bluerock Therapeutics, Katie Pollock Head of Formulation and Cryobiology Bristol-Myers Squibb, Olivier Godeaux CMO Bone Therapeutics, Jean-Pierre Latere COO Celyad, Elizabeth Garner Principal Scientist Caribou Biosciences, Luis Borges CSO Century Therapeutics, Demetrios Kalaitzidis Director, ImmunoOncology CRISPR Therapeutics, Bob Valamehr CDO Fate Therapeutics, Oliver Nussbaumer Head of Immunology GammaDelta Therapeutics, Dominic Clarke Global Head of Cell Therapy HemaCare Corporation, Yannick Bulliard Director, Translational Science Immatics, Lawrence Lamb CSO Incysus Therapeutics, Chris Bond VP, Cellular Engineering Kite Pharma, Andy Snowden Senior Director, Process Development Kite Pharma, Marcos Langtry Head of Allogeneic Cell Therapy Commercial Development Lonza Pharma and Biotech, Jean-François Chaubard CTO MaSTheCell, Tamara Laskowski Senior Research Scientist, Immunotherapy MD Anderson Center, Meisam Naeimi Postdoctoral Fellow Nationwide Children's Hospital, Hans Klingemann VP, R and D NantKwest, Guanglin Yu Senior Scientist Novartis, Sumithira Vasu Associate Professor The Ohio State University, Stacey Cranert Senior Scientist Poseida Therapeutics, Chris Heery CMO Precision BioSciences, Dan MacLeod Head of Cell Therapy Precision Biosciences, Jonathan Gilbert Head of Business Development SQZ Biotechnologies, Chelsea Xue Director, Head of Analytics, Cell Therapy Takeda, Lan Cao Senior Director, Head of Product Development and Global Program Leader, Cell Therapy Takeda, Dario Gutierrez VP, Discovery, Research and Innovation TCR2 Therapeutics , Michael Leek CEO TCBiopharm, Bruce Bunnell Professor and Director Tulane University of Louisiana, Evren Alici CEO Vycellix